ORGANON REMERON IS FIRST ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANT RECOMMENDED BY ADVISORY COMMITTEE; LABELING SHOULD NOTE NEUTROPENIA RISK
Organon's Remeron (mirtazapine) is the first alpha2-receptor antagonist recommended for approval for the treatment of depression by FDA's Psychopharmacologic Drugs Advisory Committee. On two unanimous votes Oct. 16 the committee agreed Remeron (NDA 20-415) is safe and effective for the requested indication.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth